279 related articles for article (PubMed ID: 32712104)
1. FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to Specific DNA Motifs.
Ramos Pittol JM; Milona A; Morris I; Willemsen ECL; van der Veen SW; Kalkhoven E; van Mil SWC
Gastroenterology; 2020 Nov; 159(5):1853-1865.e10. PubMed ID: 32712104
[TBL] [Abstract][Full Text] [Related]
2. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation.
Zhang Y; Kast-Woelbern HR; Edwards PA
J Biol Chem; 2003 Jan; 278(1):104-10. PubMed ID: 12393883
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic insights into isoform-dependent and species-specific regulation of bile salt export pump by farnesoid X receptor.
Song X; Chen Y; Valanejad L; Kaimal R; Yan B; Stoner M; Deng R
J Lipid Res; 2013 Nov; 54(11):3030-44. PubMed ID: 24002920
[TBL] [Abstract][Full Text] [Related]
4. Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice.
Massafra V; Milona A; Vos HR; Ramos RJJ; Gerrits J; Willemsen ECL; Ramos Pittol JM; Ijssennagger N; Houweling M; Prinsen HCMT; Verhoeven-Duif NM; Burgering BMT; van Mil SWC
Gastroenterology; 2017 May; 152(6):1462-1476.e10. PubMed ID: 28130067
[TBL] [Abstract][Full Text] [Related]
5. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
6. Hepatic farnesoid X-receptor isoforms α2 and α4 differentially modulate bile salt and lipoprotein metabolism in mice.
Boesjes M; Bloks VW; Hageman J; Bos T; van Dijk TH; Havinga R; Wolters H; Jonker JW; Kuipers F; Groen AK
PLoS One; 2014; 9(12):e115028. PubMed ID: 25506828
[TBL] [Abstract][Full Text] [Related]
7. The hepatic orosomucoid/α1-acid glycoprotein gene cluster is regulated by the nuclear bile acid receptor FXR.
Porez G; Gross B; Prawitt J; Gheeraert C; Berrabah W; Alexandre J; Staels B; Lefebvre P
Endocrinology; 2013 Oct; 154(10):3690-701. PubMed ID: 23861371
[TBL] [Abstract][Full Text] [Related]
8. Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR.
Dong B; Singh AB; Guo GL; Young M; Liu J
Int J Mol Med; 2019 May; 43(5):1927-1938. PubMed ID: 30896855
[TBL] [Abstract][Full Text] [Related]
9. Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding.
Kay HY; Kim WD; Hwang SJ; Choi HS; Gilroy RK; Wan YJ; Kim SG
Antioxid Redox Signal; 2011 Oct; 15(8):2135-46. PubMed ID: 21504366
[TBL] [Abstract][Full Text] [Related]
10. SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes.
Balasubramaniyan N; Luo Y; Sun AQ; Suchy FJ
J Biol Chem; 2013 May; 288(19):13850-62. PubMed ID: 23546875
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
12. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
[TBL] [Abstract][Full Text] [Related]
13. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
14. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model.
Deuschle U; Schüler J; Schulz A; Schlüter T; Kinzel O; Abel U; Kremoser C
PLoS One; 2012; 7(10):e43044. PubMed ID: 23056173
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
[TBL] [Abstract][Full Text] [Related]
16. Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism.
Correia JC; Massart J; de Boer JF; Porsmyr-Palmertz M; Martínez-Redondo V; Agudelo LZ; Sinha I; Meierhofer D; Ribeiro V; Björnholm M; Sauer S; Dahlman-Wright K; Zierath JR; Groen AK; Ruas JL
Mol Metab; 2015 Dec; 4(12):891-902. PubMed ID: 26909306
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of novel splice variants of human farnesoid X receptor.
Mustonen EK; Lee SML; Nieß H; Schwab M; Pantsar T; Burk O
Arch Biochem Biophys; 2021 Jul; 705():108893. PubMed ID: 33930378
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.
Claudel T; Inoue Y; Barbier O; Duran-Sandoval D; Kosykh V; Fruchart J; Fruchart JC; Gonzalez FJ; Staels B
Gastroenterology; 2003 Aug; 125(2):544-55. PubMed ID: 12891557
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy.
Xing X; Burgermeister E; Geisler F; Einwächter H; Fan L; Hiber M; Rauser S; Walch A; Röcken C; Ebeling M; Wright MB; Schmid RM; Ebert MP
Hepatology; 2009 Mar; 49(3):979-88. PubMed ID: 19072826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
